Lucentis prefilled syringe now available for all forms of diabetic retinopathy

The Lucentis 0.3 mg prefilled syringe can now be ordered by ophthalmologists in the United States for the treatment of all forms of diabetic retinopathy, Genentech announced in correspondence with Healio.com/OSN.

The prefilled syringe was approved by the FDA for all forms of diabetic retinopathy, with or without diabetic macular edema, in March. In 2016, the Lucentis (ranibizumab) 0.5 mg prefilled syringe was approved for wet age-related macular degeneration, macular edema after retinal vein occlusion and myopic choroidal neovascularization.

The syringe is made of borosilicate glass and packaged in a single-use sterile sealed tray, allowing physicians to eliminate steps in preparing and administering the drug.

The Lucentis 0.3 mg prefilled syringe can now be ordered by ophthalmologists in the United States for the treatment of all forms of diabetic retinopathy, Genentech announced in correspondence with Healio.com/OSN.

The prefilled syringe was approved by the FDA for all forms of diabetic retinopathy, with or without diabetic macular edema, in March. In 2016, the Lucentis (ranibizumab) 0.5 mg prefilled syringe was approved for wet age-related macular degeneration, macular edema after retinal vein occlusion and myopic choroidal neovascularization.

The syringe is made of borosilicate glass and packaged in a single-use sterile sealed tray, allowing physicians to eliminate steps in preparing and administering the drug.